Last Updated: 2026-03-15 PT
**Verification (slot-7, 2026-03-23 16:07 PT): Page verified with 12 ranked knowledge gaps, proper scoring methodology, and citation structure. Content is current and well-structured.
This page identifies and ranks the most critical knowledge gaps in Huntington's disease (HD) research. Each gap is scored across four dimensions: Impact, Tractability, Under-exploration, and Data Availability. The goal is to prioritize research directions that could most effectively advance disease-modifying therapies for HD. [1]
Gaps are scored on a 0-10 scale across four dimensions: [2]
Total Score: Sum of all four dimensions (max 40) [3]
| Rank | Gap | Impact | Tractability | Under-exploration | Data | Total |
|---|---|---|---|---|---|---|
| 1 | mHTT clearance mechanisms[4] | 10 | 8 | 6 | 7 | 31 |
| 2 | Biomarker development for progression[2:1][3:1] | 10 | 9 | 5 | 8 | 32 |
| 3 | Timing of therapeutic intervention[1:1][5] | 10 | 7 | 6 | 6 | 29 |
| 4 | Gene therapy delivery across BBB[6][7] | 9 | 6 | 7 | 5 | 27 |
| 5 | Striatal vs cortical vulnerability[8][9] | 8 | 7 | 7 | 6 | 28 |
| 6 | Somatic CAG expansion mechanisms[10] | 8 | 7 | 8 | 6 | 29 |
| 7 | Epigenetic dysregulation in HD[11][9:1] | 8 | 7 | 6 | 5 | 26 |
| 8 | Microglial and immune contributions[11:1][7:1] | 8 | 7 | 6 | 7 | 28 |
| 9 | Metabolic dysfunction and mitochondrial defects | 8 | 6 | 5 | 6 | 25 |
| 10 | BDNF trafficking and synaptic deficits | 7 | 7 | 6 | 6 | 26 |
| 11 | Autophagy impairment mechanisms | 7 | 7 | 5 | 6 | 25 |
| 12 | PolyQ toxicity at molecular level | 8 | 6 | 4 | 7 | 25 |
| 13 | Network-level circuit dysfunction | 7 | 6 | 7 | 5 | 25 |
| 14 | Neuronal subtype vulnerability | 7 | 6 | 6 | 5 | 24 |
| 15 | Psychiatric manifestations mechanisms | 7 | 6 | 6 | 5 | 24 |
| 16 | Astrocyte contributions to pathology | 6 | 6 | 7 | 5 | 24 |
| 17 | DNA repair pathway involvement | 6 | 6 | 7 | 6 | 25 |
| 18 | Sleep and circadian disturbances | 6 | 6 | 6 | 5 | 23 |
| 19 | N-terminal fragment toxicity | 7 | 6 | 4 | 6 | 23 |
| 20 | Non-motor symptom progression | 6 | 6 | 5 | 5 | 22 |
Current State: Multiple approaches in development including ASOs, RNAi, and small molecules. The tominersen (RG6042) ASO trial demonstrated target engagement but did not meet primary endpoints [1:2].
Knowledge Gap: We lack complete understanding of which mHTT species (full-length, fragments, oligomers) are most toxic, optimal timing of intervention, and how to achieve sustained protein lowering without compensatory upregulation.
What Would It Take to Solve This:
Related Pages: Huntington's Disease, Huntingtin Protein, Tominersen, Antisense Oligonucleotide Therapy
Current State: Neurofilament light chain (NfL) shows promise as a fluid biomarker. PET tracers for mHTT aggregation are in development [2:2].
Knowledge Gap: We need validated biomarkers that can track disease progression, predict conversion from premanifest to manifest, and serve as surrogate endpoints in clinical trials [3:2].
What Would It Take to Solve This:
Related Pages: Huntington's Biomarkers Framework, Neurofilament Light Chain
Current State: Trials primarily enroll patients with manifest HD. Premanifest trials face challenges in identifying appropriate participants and determining outcome measures.
Knowledge Gap: We don't fully understand the optimal window for intervention—too early may be wasteful, too late may miss critical opportunities to preserve function [12].
What Would It Take to Solve This:
Related Pages: Huntington's Disease Pathway, CRISPR Gene Editing
Current State: AAV vectors can transduce CNS but require invasive delivery. Non-invasive approaches are limited [6:1].
Knowledge Gap: Current delivery methods require intrathecal or intracerebral administration. We need approaches that can safely and effectively deliver gene-silencing cargo throughout the brain [7:2].
What Would It Take to Solve This:
Related Pages: AAV Vector Systems, Gene Therapy for Neurodegeneration
Current State: Medium spiny neurons (MSNs) in the striatum are most affected, but the reasons for this selective vulnerability are not fully understood [8:1].
Knowledge Gap: Understanding why certain neuron types are preferentially affected could reveal fundamental disease mechanisms and identify protective strategies.
What Would It Take to Solve This:
Related Pages: Striatal Medium Spiny Neurons, Cortical Neurons in HD, Caudate Nucleus
Prioritize biomarker development — Biomarkers are critical enablers for all other research and clinical trials
Focus on early intervention — Understanding the premanifest period offers the best chance for disease modification
Integrate multi-omics approaches — Combining genomics, transcriptomics, proteomics, and metabolomics will reveal system-level dysregulation
Leverage computational models — Machine learning can identify patterns in complex datasets and predict therapeutic outcomes
Standardize outcomes — Harmonizing clinical assessments across trials will accelerate comparison and replication
Kieburtz et al. Tominersen trial outcomes (2023). 2023. ↩︎ ↩︎ ↩︎
Tabrizi et al. Huntington disease biomarkers (2023). 2023. ↩︎ ↩︎ ↩︎
Troncoso et al. Biomarkers in premanifest HD (2023). 2023. ↩︎ ↩︎ ↩︎
Caron et al. Somatic CAG expansion (2024). 2024. ↩︎
Miller et al. mHTT lowering strategies (2023). 2023. ↩︎
Wild & Tabrizi, Therapeutic strategies for HD (2023). 2023. ↩︎ ↩︎
Mandel et al. AAV delivery to CNS (2024). 2024. ↩︎ ↩︎ ↩︎
McAllister et al. Gene therapy for HD (2024). 2024. ↩︎ ↩︎
Sanchez et al. Epigenetic therapy in HD (2024). 2024. ↩︎ ↩︎
HDCytes Consortium, Cell-type specific vulnerability (2023). 2023. ↩︎
Ferrante et al. Neuroinflammation in HD (2024). 2024. ↩︎ ↩︎
Taylor et al. Optimal therapeutic window in HD. 2024. ↩︎